Immunogenicity of A 23-Valent Pneumococcal Polysaccharide Vaccine Among Mexican Children

Archives of Medical Research

Volumn 43, Issue 5, 2012, Pages 402-405

  Espinosa Padilla, Sara Elva ^a   Murata, Chiharu ^a   Estrada Parra, Sergio ^b   Santos Argumedo, Leopoldo ^c   Mascareñas, Cesar ^d   Franco Paredes, Carlos ^e   Espinosa Rosales, Francisco Javier ^a  

^a INSTITUTO NACIONAL DE PEDIATRÍA   (Mexico)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^c DEPARTAMENTO DE FÍSICA   (Mexico)

^d Medical Department Latinamerica   (Mexico)

^e HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

Author keywords

Immunogenicity; Polysaccharide; Streptococcus pneumoniae; Vaccine

Indexed keywords

IMMUNOGLOBULIN G; PNEUMOCOCCUS VACCINE;

ANTIBODY TITER; ARTICLE; CHILD; CHILDHOOD DISEASE; CONTROLLED STUDY; DRUG FEVER; DRUG SAFETY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; MEXICO; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEROTYPE; VACCINATION;

ANTIBODIES, BACTERIAL; CHILD, PRESCHOOL; HUMANS; IMMUNOGLOBULIN G; INFANT; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; POLYSACCHARIDES, BACTERIAL; PROSPECTIVE STUDIES; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 84866146283     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2012.07.005     Document Type: Article

References (18)

1. O'Brien K.L., Wolfson L.J., Watt J.P., et al. Hib and Pneumococcal Global Burden of Disease Study Team. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: Global estimates. Lancet 2009, 374:893-902.
2. Echaniz-Aviles G., Carnalla-Barajas M., Velásquez-Meza M.E., et al. Capsular types of Streptococcus pneumoniae causing disease in children from Mexico City. Pediatr Infect Dis J 1995, 14:907-909.
3. Echaniz-Avilés G., Velázquez-Meza M.E., Carnalla-Barajas M.N., et al. Antimicrobial susceptibilities and capsular types of invasive Streptococcus pneumoniae isolated in children in Mexico City. Micros Drug Resist 1997, 3:153-157.
4. Hortal M., Ruvinsky R., Rossi A., et al. Impacto de Streptococcus pneumoniae en las neumonías del niño latinoamericano. Grupo SIREVA-Vigía. Rev Panam Salud Pública 2000, 8:185-195.
5. Wernette C.M., Frasch C.E., Madore D., et al. Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol 2003, 10:514-519.
6. Quataert S.A., Kirch C.S., Wiedl L.J., et al. Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S. Clin Diagn Lab Immunol 1995, 2:590-597.
7. Concepcion N.F., Frasch C.E. Pneumococcal type 22F polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 2001, 8:266-272.
8. Quataert S.A., Rittenhouse-Olson K., Kirch C.S., et al. Assignment of weight-based antibody units for 13 serotypes to a human antipneumococcal standard reference serum, lot 89-S(f). Clin Diagn Lab Immunol 2004, 11:1064-1069.
9. Pomat W.S., Lehmann D., Sanders R.C., et al. Immunoglobulin G antibody responses to polyvalent pneumococcal vaccine in children in the highlands of Papua New Guinea. Infect Immun 1994, 62:1848-1853.
10. Anttila M., Eskola J., Ahman H., et al. Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines. J Infect Dis 1998, 177:1614-1621.
11. Huang S.S., Hinrichsen V.L., Stevenson A.E., et al. Continued impact of pneumococcal conjugate vaccine on carriage in young children. Pediatrics 2009, 124:e1-e11.
12. Bryant K.A., Block S.L., Baker S.A., et al. PCV13 Infant Study Group. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. Pediatrics 2010, 125:866-875.
13. Sinha A., Constenla D., Valencia J.E., et al. Cost-effectiveness of pneumococcal conjugate vaccination in Latin America and the Caribbean: a regional analysis. Rev Panam Salud Publica 2008, 24:304-313.
14. Temple K., Greenwood B., Inskip H., et al. Antibody response to pneumococcal capsular polysaccharide vaccine in African children. Pediatr Infect Dis J 1991, 10:386-390.
15. Koskela M., Leinonen M., Haiva V.M., et al. First and second dose antibody responses to pneumococcal polysaccharide vaccine in infants. Pediatr Infect Dis 1986, 5:45-50.
16. Borgono J.M., McLean A.A., Vella P.P., et al. Vaccination and revaccination with polyvalent pneumococcal polysaccharide vaccines in adults and infants. Proc Soc Exp Biol Med 1978, 157:148-154.
17. Leinonen M., Sakkinen A., Kalliokoski R., et al. Antibody response to 14-valent pneumococcal capsular polysaccharide vaccine in pre-school age children. Pediatr Infect Dis 1986, 5:39-44.
18. Russell F.M., Carapetis J.R., Balloch A., et al. Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial. Vaccine 2010, 28:3341-3349.